Literature DB >> 20649596

Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.

E L Hardaker1, M S Freeman, N Dale, P Bahra, F Raza, K H Banner, C Poll.   

Abstract

BACKGROUND AND
PURPOSE: Acute exacerbations of chronic obstructive pulmonary disease (COPD), which are often associated with respiratory infections, are defined as a worsening of symptoms that require a change in medication. Exacerbations are characterized by a reduction in lung function, quality of life and are associated with increased pro-inflammatory mediators in the lung. Our aim was to develop an animal model to mimic aspects of this exaggerated inflammatory response by combining key etiological factors, tobacco smoke (TS) and bacterial lipopolysaccharide (LPS). EXPERIMENTAL APPROACH: Rats were exposed to TS for 30 min twice a day for 2 days. On day 3 animals were exposed to LPS for 30 min followed by exposure to TS 5 h later. Inflammation, mucus and lung function were assessed 24 h after LPS. KEY
RESULTS: Neutrophils, mucus, oedema and cytotoxicity in lung and/or bronchoalveolar lavage was increased in animals exposed to combined LPS and TS, compared with either stimulus alone. Lung function was impaired in animals exposed to combined LPS and TS. Inflammatory cells, oedema and mucus were unaffected by pretreatment with the corticosteroid, budesonide, but were reduced by the phosphodiesterase 4 selective inhibitor roflumilast. Additionally, lung function was improved by roflumilast. CONCLUSIONS AND IMPLICATIONS: We have established an in vivo model mimicking characteristic features of acute exacerbations of COPD including lung function decline and increased lung inflammation. This model may be useful to investigate molecular and cellular mechanisms underlying such exacerbations, to identify new targets and to discover novel therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649596      PMCID: PMC2958644          DOI: 10.1111/j.1476-5381.2010.00857.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  The economic burden of COPD.

Authors:  S D Sullivan; S D Ramsey; T A Lee
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

2.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; A Bhowmik; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

3.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

Review 4.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary.

Authors:  R A Pauwels; A S Buist; P Ma; C R Jenkins; S S Hurd
Journal:  Respir Care       Date:  2001-08       Impact factor: 2.258

Review 5.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

6.  Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease.

Authors:  S V Culpitt; W Maziak; S Loukidis; J A Nightingale; J L Matthews; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

7.  Changes in bronchial inflammation during acute exacerbations of chronic bronchitis.

Authors:  S Gompertz; C O'Brien; D L Bayley; S L Hill; R A Stockley
Journal:  Eur Respir J       Date:  2001-06       Impact factor: 16.671

8.  Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group.

Authors:  M Miravitlles; T Guerrero; C Mayordomo; L Sánchez-Agudo; F Nicolau; J L Segú
Journal:  Respiration       Date:  2000       Impact factor: 3.580

9.  Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease.

Authors:  S D Aaron; J B Angel; M Lunau; K Wright; C Fex; N Le Saux; R E Dales
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

10.  Bacteria challenge in smoke-exposed mice exacerbates inflammation and skews the inflammatory profile.

Authors:  Gordon J Gaschler; Marko Skrtic; Caleb C J Zavitz; Maria Lindahl; Per-Ola Onnervik; Timothy F Murphy; Sanjay Sethi; Martin R Stämpfli
Journal:  Am J Respir Crit Care Med       Date:  2009-01-29       Impact factor: 21.405

View more
  18 in total

Review 1.  Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Authors:  Klaus F Rabe
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

2.  Therapeutic Effects of Resveratrol in a Mouse Model of LPS and Cigarette Smoke-Induced COPD.

Authors:  Jinlong Chen; Xu Yang; Weiya Zhang; Danhua Peng; Yanan Xia; Yi Lu; Xiaodong Han; Guangjie Song; Jing Zhu; Renping Liu
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

3.  Curcumin Attenuates Airway Inflammation and Airway Remolding by Inhibiting NF-κB Signaling and COX-2 in Cigarette Smoke-Induced COPD Mice.

Authors:  Jin Yuan; Renping Liu; Yaohui Ma; Zhaoqiang Zhang; Zehao Xie
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

4.  The ion channel transient receptor potential melastatin-2 does not play a role in inflammatory mouse models of chronic obstructive pulmonary diseases.

Authors:  Liz Hardaker; Parmjit Bahra; Benjamin Cochin de Billy; Mark Freeman; Natalia Kupfer; Daniel Wyss; Alexandre Trifilieff
Journal:  Respir Res       Date:  2012-04-04

5.  The human laryngeal microbiome: effects of cigarette smoke and reflux.

Authors:  Marie E Jetté; Kimberly A Dill-McFarland; Alissa S Hanshew; Garret Suen; Susan L Thibeault
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

6.  Mitochondrial Transplantation Attenuates Airway Hyperresponsiveness by Inhibition of Cholinergic Hyperactivity.

Authors:  Yuan Su; Liping Zhu; Xiangyuan Yu; Lei Cai; Yankai Lu; Jiwei Zhang; Tongfei Li; Jiansha Li; Jingyan Xia; Feng Xu; Qinghua Hu
Journal:  Theranostics       Date:  2016-05-24       Impact factor: 11.556

Review 7.  Experimental animal models for COPD: a methodological review.

Authors:  Vahideh Ghorani; Mohammad Hossein Boskabady; Mohammad Reza Khazdair; Majid Kianmeher
Journal:  Tob Induc Dis       Date:  2017-05-02       Impact factor: 2.600

8.  Neutrophil extracellular traps promote lipopolysaccharide-induced airway inflammation and mucus hypersecretion in mice.

Authors:  Yong Zou; Xi Chen; Jian Xiao; Dong Bo Zhou; Xiao Xiao Lu; Wei Li; Bin Xie; Xiao Kuang; Qiong Chen
Journal:  Oncotarget       Date:  2018-01-08

9.  Respiratory infections cause the release of extracellular vesicles: implications in exacerbation of asthma/COPD.

Authors:  Suffwan Eltom; Nicole Dale; Kristof R G Raemdonck; Christopher S Stevenson; Robert J Snelgrove; Pradeep K Sacitharan; Chiara Recchi; Silene Wavre-Shapton; Daniel F McAuley; Cecilia O'Kane; Maria G Belvisi; Mark A Birrell
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

10.  The Isosteroid Alkaloid Imperialine from Bulbs of Fritillaria cirrhosa Mitigates Pulmonary Functional and Structural Impairment and Suppresses Inflammatory Response in a COPD-Like Rat Model.

Authors:  Dongdong Wang; Qingdan Du; Houcong Li; Shu Wang
Journal:  Mediators Inflamm       Date:  2016-07-20       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.